Easylife Health Announces Launch of 'Ovarian Health Assessment' – A Home-Based Endocrine Testing Solution for 100 Million Women

From June 14 to 18, the 6th Future Healthcare Top 100 Conference, themed “China Stories,” was successfully held, attracting thousands of industry elites from home and abroad to gather in the cloud. Home testing and health management product and service providersTesting OneLifeAttended by invitation and launched its first product at the conference“Ovarian Health Assessment”. It is understood that the product is primarily targeted at women aged 18–35, aiming to help them comprehensively assess their ovarian reserve function, provide early warnings of health risks, and offer interpretation and appropriate intervention services. It will be officially launched in September.

Currently, China's female health management market is experiencing continuous annual growth. According to Frost & Sullivan statistics, the market size of female health management platforms grew from RMB 510 million in 2013 to RMB 13.0 billion in 2018, representing a compound annual growth rate (CAGR) of 91.3%, and is projected to reach RMB 47.17 billion by 2024. In reality, a substantial portion of demand for female health management remains unmet, including areas such as menopause management, women's mental health management, and endocrine health management.

Against this backdrop, Testing OneLife has entered the niche market of female endocrine health. Leveraging its self-built laboratory to provide precise in vitro diagnostic technologies, and integrating big data with artificial intelligence, the company has established a cloud-based health monitoring system with personalized report interpretation under the “Lifelong Renewal” framework. This approach creates a closed-loop system for at-home female endocrine testing and digital health management. This time“Ovarian Health Assessment”The rapid launch of the product also attests to Testing OneLife Laboratory’s mature R&D capabilities and the stability of its testing system.

Regarding the choice of “ovaries” as the entry point for its inaugural product, Wang Qiangyu, Founder and CEO of Testing OneLife, stated: “The female ovaries serve dual roles in reproduction and maintaining endocrine homeostasis. They are critical not only to a woman’s own safety and health but also influence the constitution and well-being of the next generation. By focusing on ovarian health, implementing proactive health management, and exploring effective and safe strategies to intervene in ovarian aging and disease, we aim to safeguard women’s endocrine health throughout their entire life cycle.”

It is understood that the ones unveiled this time“Ovarian Health Assessment”The core testing indicator of the product is AMH (Anti-Müllerian Hormone), which is recognized as the gold standard for assessing female ovarian reserve. To ensure simple sampling while guaranteeing the safety and accuracy of the test, Testing OneLife has uniquely developed aMicro-Volume Peripheral Blood Collection Device, integrating precise 50 μL quantitative sampling and drying into a single unit, experimental results demonstrate that capillary blood can be stably preserved for 7 days or even longer.

Furthermore, Testing OneLife conducted a 10-month clinical validation involving 1,000 cases. The data showed that the test results from dried blood spots (DBS) prepared with capillary blood (50 μL) after elution were largely consistent with those from venous plasma, with correlation coefficients for all parameters exceeding 0.93, representing a leading level in China.

It is important to note that there are two models for home testing available on the market: point-of-care testing (POCT) and laboratory-based testing. The POCT model offers a relatively limited range of detectable indicators and lacks sufficient accuracy. In contrast, the laboratory-based testing model demonstrates greater compatibility with various sample types and higher precision. However, most previous laboratory-based testing methods required venous blood draws, which users could not perform themselves, thereby hindering the development of this model. Testing OneLife’s innovative model of quantitative capillary blood collection overcomes the historical drawback of cumbersome sampling procedures, enabling precise testing to “truly” extend into home settings. This approach lowers the barrier to use for consumers and is poised to accelerate industry-wide adoption.

“True closed-loop services require not only precise initial testing but also critical mid-stage report interpretation and subsequent health interventions.” Wang Qiangyu believes that to achieve effective health management, it is essential first to enable users to understand their reports, rather than overwhelming them with complex data and professional jargon. Subsequent health interventions should be tailored to the user’s specific circumstances, providing targeted health management and online consultations, while collaborating with offline hospitals and internet hospitals to facilitate patient care.

It is understood that Testing OneLife has hired professional reproductive endocrinologists and collaborated with medical teams from Grade A tertiary hospitals to completely redesign traditional test reports. By integrating global authoritative guidelines and expert consensus, the company provides comprehensive and easy-to-understand interpretations and health management recommendations tailored to users’ biomarker profiles, warns of health risk factors, and offers scientifically grounded lifestyle management pathways. Furthermore, for users with abnormal indicators or those who are highly concerned about their health, Testing OneLife will also offer services such as one-on-one consultations and health monitoring management.

At the Future Healthcare 100 Conference, Testing OneLife returned with honors. Leveraging its professional founding team, leading precision micro-testing technology, and an innovative internet-based business model, Testing OneLife was listed among the “2022 Future Healthcare 100 · China Innovative Digital Health Top 100” and also received the “2022 Future Healthcare 100 · Pengcheng Award · Enterprise of the Year with Potential.” This recognition and award are not only a testament to its strength but also a reminder of its responsibilities. Looking ahead, we anticipate that Testing OneLife will continue to innovate and develop more products, delivering greater value through home testing and health management solutions for users.